Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Necrotizing Enterocolitis (Nec) and B. Lactis in Premature Babies

This study has been terminated.
Information provided by (Responsible Party):
Nestlé Identifier:
First received: September 15, 2009
Last updated: November 22, 2013
Last verified: November 2013
The purpose of the trial is to demonstrate the effect of B. lactis in reducing the incidence of Necrotizing Enterocolitis (NEC) compared to placebo in preterm infants.

Condition Intervention
Necrotizing Enterocolitis
Dietary Supplement: Probiotic supplementation
Dietary Supplement: Milk containing placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prevention of NEC in Preterm Infants With B. Lactis

Resource links provided by NLM:

Further study details as provided by Nestlé:

Primary Outcome Measures:
  • NEC onset [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Antibiotic administration and stool microbiology [ Time Frame: 6 weeks ]

Enrollment: 318
Study Start Date: November 2009
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: "Milk" containing B. Lactis
"Milk" = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula.
Dietary Supplement: Probiotic supplementation
one capsule containing probiotics per day added to milk
Placebo Comparator: "Milk" containing placebo
"Milk" = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula.
Dietary Supplement: Milk containing placebo
one capsule containing placebo per day added to milk


Ages Eligible for Study:   up to 48 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Weight between 800 - 1500g
  • Tolerating enteral feeding within 48 hours
  • Having obtained his/her parents or legal representative informed consent

Exclusion Criteria:

  • Chromosomal abnormality
  • Hydrops featalis
  • Congenital malformation of the gastrointestinal tract
  • Congenital heart defects or other major congenital abnormalities likely to affect feeding and/or feeding tolerance
  • Currently participating in another clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00977912

South Africa
University of Witwatersrand & Chris Hani Baragwanath Hospital
Bertsham, South Africa, 2013
University of Witwatetersrand & Charlotte Maxek Johannestburg Academic Hospital
Johannesburg, South Africa, 2000
University of Witwatersrand & Rahima Moosa Mother & Child Hospital
Johannesburg, South Africa, 2112
Sponsors and Collaborators
Principal Investigator: Peter A. Cooper, MD University of Witwatetersrand & Charlotte Maxek Johannestburg Academic Hospital
  More Information

Responsible Party: Nestlé Identifier: NCT00977912     History of Changes
Other Study ID Numbers: 08.09.INF
Study First Received: September 15, 2009
Last Updated: November 22, 2013

Keywords provided by Nestlé:
B. lactis
Necrotizing Enterocolitis (NEC)

Additional relevant MeSH terms:
Enterocolitis, Necrotizing
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on April 28, 2017